Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523486 | 0.96 | CTSK (0.59) | CTSKUSP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL3603586 | 0.92 | CTSK (0.72) | CTSKUSP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL900812 | 0.87 | CTSK (0.67) | CTSKUSP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL14335386 | 0.82 | CTSK (0.45) | CTSKUSP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL9470186 | 0.81 | CTSK (0.65) | CTSKUSP2SMN1; SMN2HPGDMEN1 | |
| Hydrochloric Acid SCHEMBL14335352 | 0.80 | CTSK (0.44) | CTSKUSP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL1190545 | 0.80 | CTSK (0.59) | CTSKUSP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL6023110 | 0.79 | CTSK (0.43) | CTSKUSP2SMN1; SMN2HPGDCHRM2 | |
| SCHEMBL6203340 | 0.78 | CTSK (0.45) | CTSKUSP2SMN1; SMN2HPGDMEN1 | |
| SCHEMBL18997752 | 0.78 | CTSK (0.57) | CTSKUSP2SMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20200172575-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| EP-3650464-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-20100056505-A1 | Substituted Pyrazalones | BIOGEN IDEC MA INC. | 2010-03-04 | — | — | US | disclosed |
| EP-1971594-A2 | SUBSTITUTED PYRAZALONES | Biogen Idec MA Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007059359-A2 | SUBSTITUTED PYRAZALONES | BIOGEN IDEC MA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-5494889-A | THIADIAZABICYCLOOCTANE AND THIADIAZABICYCLOOCTENE DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0639196-A1 | NEW HERBICIDES | Novartis AG (CH) | 1995-02-22 | — | — | EP | disclosed |
| WO-1992021684-A1 | NEW HERBICIDES | CIBA-GEIGY AG (CH) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SLC10A2, SLC10A1, BCAT2 | CTSK 4241/4885USP2 1428/4885SMN1; SMN2 2918/4885 |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, NPY1R | CTSK 1962/4885USP2 2873/4885SMN1; SMN2 3197/4885 |
| US-20100056505-A1 | Substituted Pyrazalones | ACVR1, ACVRL1, TGFBR1 | CTSK 1737/4885USP2 4456/4885SMN1; SMN2 4777/4885 |
| US-20200172575-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | KISS1R, VIP, NPY1R | CTSK 1962/4885USP2 2873/4885SMN1; SMN2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.